Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Change in Account Payables: 2014-2024

Historic Change in Account Payables for Syndax Pharmaceuticals (SNDX) over the last 11 years, with Dec 2024 value amounting to $1.7 million.

  • Syndax Pharmaceuticals' Change in Account Payables rose 47.12% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.9 million, marking a year-over-year increase of 875.67%. This contributed to the annual value of $1.7 million for FY2024, which is 70.33% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Change in Account Payables stood at $1.7 million for FY2024, which was down 70.33% from $5.6 million recorded in FY2023.
  • Over the past 5 years, Syndax Pharmaceuticals' Change in Account Payables peaked at $5.6 million during FY2023, and registered a low of -$2.7 million during FY2020.
  • In the last 3 years, Syndax Pharmaceuticals' Change in Account Payables had a median value of $1.7 million in 2024 and averaged $2.0 million.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Change in Account Payables crashed by 161.04% in 2022 and then skyrocketed by 525.40% in 2023.
  • Yearly analysis of 5 years shows Syndax Pharmaceuticals' Change in Account Payables stood at -$2.7 million in 2020, then surged by 180.94% to $2.2 million in 2021, then tumbled by 161.04% to -$1.3 million in 2022, then spiked by 525.40% to $5.6 million in 2023, then plummeted by 70.33% to $1.7 million in 2024.